US Patent

US12097202 — Methods of administering Belumosudil for treatment of chronic graft versus host disease

Method of Use · Assigned to Kadmon Corp LLC · Expires 2042-07-14 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of administering belumosudil mesylate salt to treat chronic graft-versus-host disease by modifying administration based on patient adverse reactions.

USPTO Abstract

The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4014 — belumosudil-mesylate

Patent Metadata

Patent number
US12097202
Jurisdiction
US
Classification
Method of Use
Expires
2042-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Kadmon Corp LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.